Abstract| Volume 57, ISSUE 2, P274-275, August 2019

Download started.


Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial

Dalziel SR, Borland ML, Furyk J, et al. The Lancet. 2019; 393:2135-2145
      Current literature supports benzodiazepines as first-line treatment in pediatric convulsive status epilepticus, but low quality evidence exists to support current guideline recommendations of phenytoin and fosphenytoin as second-line agents. Additionally, current evidence suggests increased risk of adverse events with phenytoin and there have been cases of fatal loading dose errors. Levetiracetam has emerged as a popular option due to its favorable safety profile. This study examined the comparative efficacy of levetiracetam and phenytoin as second-line agents for the treatment of pediatric convulsive status epilepticus. In particular, it sought to provide further evidence of the superiority of levetiracetam compared to phenytoin based on previous retrospective data.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect